Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Christian Tjiam
Observed names:
Christian Tjiam,
M Christian Tjiam,
M. C. Tjiam,
M.C. Tjiam,
MC Tjiam,
Tjiam MC,
Tjiam, Christian
show all 7
Institutions:
The Kids Research Institute Australia,
The University of Western Australia
Observed institutions:
The Kids Research Institute Australia,
The University of Western Australia,
Curtin University,
Royal Perth Hospital,
UNSW Sydney,
Pathwest Laboratory Medicine,
Kirby Institute
show all 7
ORCID:
0000-0002-1207-4811
Observed ORCID:
0000-0002-1207-4811
OpenAlex ID:
A5067948445
Single-nucleus RNA sequencing of pre-malignant liver reveals disease-associated hepatocyte state with HCC prognostic potential
2023
·
Rodrigo Carlessi
, Elena Denisenko
, et al.
·
Cell Genomics
·
54
Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design
2017
·
Martyn A. French
, M. Christian Tjiam
, et al.
·
Frontiers in Immunology
·
35
PDF
Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell–Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification
2015
·
M Christian Tjiam
, James P A Taylor
, et al.
·
The Journal of Immunology
·
26
Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection
2017
·
Laila N. Abudulai
, Sonia Fernandez
, et al.
·
PLoS ONE
·
25
PDF
Biofilm formation on the surface of monazite and xenotime during bioleaching
2023
·
Arya van Alin
, Melissa K. Corbett
, et al.
·
Microbial Biotechnology
·
20
PDF
Characterising the Phenotypic Diversity of Antigen-Specific Memory B Cells Before and After Vaccination
2021
·
M. Christian Tjiam
, Sonia Fernandez
, et al.
·
Frontiers in Immunology
·
16
Control of early HIV-1 infection associates with plasmacytoid dendritic cell-reactive opsonophagocytic IgG antibodies to HIV-1 p24
2016
·
M. Christian Tjiam
, Lucy Sariputra
, et al.
·
AIDS
·
16
B cell epitope mapping: The journey to better vaccines and therapeutic antibodies
2024
·
Asha Joanne De Leon
, M. Christian Tjiam
, et al.
·
Biochimica et Biophysica Acta (BBA) - General Subjects
·
12
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old
2024
·
C. McLeod
, M. Dymock
, et al.
·
Journal of Infection
·
10
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)
2023
·
C. McLeod
, J Ramsay
, et al.
·
Trials
·
10
PDF
Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57:01 Is Only Observed in Viremic Controllers
2017
·
M. Christian Tjiam
, Mazmah A. Morshidi
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
9
Colostrum is required for the postnatal ontogeny of small intestine innate lymphoid type 2 cells and successful anti‐helminth defences
2024
·
Akila Rekima
, Lieke van den Elsen
, et al.
·
Allergy
·
8
Plasma testosterone concentration is correlated with circulating immune cell abundance in transgender young people on gender-affirming hormone treatment
2025
·
Alice A. White
, Thomas Pearce
, et al.
·
Frontiers in Immunology
·
6
PDF
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old
2024
·
C. McLeod
, M. Dymock
, et al.
·
Journal of Infection
·
6
PDF
Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in Mice
2024
·
Naomi Scott
, Kelly M Martinovich
, et al.
·
The Journal of Infectious Diseases
·
6
Klebsiella aerogenes Adhesion Behaviour during Biofilm Formation on Monazite
2023
·
Arya Van Alin
, Melissa K. Corbett
, et al.
·
Microorganisms
·
5
PDF
Single Nucleus RNA Sequencing of Pre-Malignant Liver Reveals Disease-Associated Hepatocyte State with HCC Prognostic Potential
2022
·
Rodrigo Carlessi
, Elena Denisenko
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
4
PDF
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol
2024
·
McLeod C
, Dymock M
, et al.
·
Trials
·
2
PDF
SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study
2026
·
Archana Koirala
, Shayal A. Prasad
, et al.
·
Vaccine
·
1
The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults
2026
·
McLeod C
, M. Dymock
, et al.
·
Vaccine
The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults
2026
·
McLeod C.
, M. Dymock
, et al.
·
Vaccine
Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae
2026
·
Jack S. Pepper
, Caitlyn M. Granland
, et al.
·
Frontiers in Immunology
PDF
PICOBOO: the immunogenicity of COVID-19 booster vaccines in individuals >12 years old
2026
·
Charlie McLeod
, Michael Dymock
, et al.
·
Australian and New Zealand Journal of Public Health
P-98. The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in BNT162b2 primed individuals aged 18-< 50 and 50-< 70 years old
2025
·
Charlie McLeod
, Michael Dymock
, et al.
·
Open Forum Infectious Diseases
PDF
86. The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-< 70 years old
2025
·
Charlie McLeod
, Michael Dymock
, et al.
·
Open Forum Infectious Diseases
PDF
Show more works
View as search
Works count:
29
Citation count:
271
H-index:
10
I10-index:
10
Year
Topic
Type